FDA approves Strativa's Nascobal spray

WOODCLIFF LAKE, N.J. — Strativa Pharmaceutical, a division of Par Pharmaceutical Cos., announced that the Food and Drug Administration approved Nascobal, a prescription B-12 supplement administered once a week as one spray.



"Unlike the current device, our new Nascobal single-use device does not require priming, which eliminates product loss. In addition, it permits patients to conveniently receive their dose with one spray per disposable device," said Rick Painter, SVP, brand sales and marketing. "Strativa remains committed to improving the product experience of the patients who rely upon us."



The device delivers 500 mcg of cyanocobalamin, USP with each spray. A carton of four single-use devices gives the patient a one month supply of Nascobal. The drug will be available in pharmacies in September.